Evidence map›Paper›PMID 29630679›Full record

ArticlePLoS pathogens2018

Protection by and maintenance of CD4 effector memory and effector T cell subsets in persistent malaria infection.

Michael M Opata, Samad A Ibitokou, Victor H Carpio, Karis M Marshall, Brian E Dillon, Jordan C Carl, Kyle D Wilson, Christine M Arcari, Robin Stephens

Abstract read
In one paragraph

Article in PLoS pathogens, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Immune Control in RepeatedOpen forum infectious diseases · 2024
    Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Michael M OpataDepartments of Internal Medicine, Division of Infectious Diseases, University of Texas Medical Branch, Galveston, TX, United States of America.
Samad A IbitokouDepartments of Internal Medicine, Division of Infectious Diseases, University of Texas Medical Branch, Galveston, TX, United States of America.ORCID 0000-0002-7760-7412
Victor H CarpioDepartment of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX, United States of America.
Karis M MarshallDepartment of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX, United States of America.
Brian E DillonDepartments of Internal Medicine, Division of Infectious Diseases, University of Texas Medical Branch, Galveston, TX, United States of America.
Jordan C CarlDepartments of Internal Medicine, Division of Infectious Diseases, University of Texas Medical Branch, Galveston, TX, United States of America.
Kyle D WilsonDepartment of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX, United States of America.
Christine M ArcariDepartment of Preventive Medicine & Community Health, University of Texas Medical Branch Galveston, TX, United States of America.ORCID 0000-0002-4753-7089
Robin StephensDepartments of Internal Medicine, Division of Infectious Diseases, University of Texas Medical Branch, Galveston, TX, United States of America.ORCID 0000-0001-8036-600X

Funding

Maintenance vs Programming in Th1 Memory Cell Development in P. Chabaudi MalariaR01AI089953 · NIAID · UNIVERSITY OF TEXAS MED BR GALVESTON · PI STEPHENS, ROBIN · 2011 to 2015
$1.8M
NIAID NIH HHS R01 AI089953
6 · The paper itself

Abstract

Protection at the peak of Plasmodium chabaudi blood-stage malaria infection is provided by CD4 T cells. We have shown that an increase in Th1 cells also correlates with protection during the persistent phase of malaria; however, it is unclear how these T cells are maintained. Persistent malaria infection promotes protection and generates both effector T cells (Teff), and effector memory T cells (Tem). We have previously defined new CD4 Teff (IL-7Rα-) subsets from Early (TeffEarly, CD62LhiCD27+) to Late (TeffLate, CD62LloCD27-) activation states. Here, we tested these effector and memory T cell subsets for their ability to survive and protect in vivo. We found that both polyclonal and P. chabaudi Merozoite Surface Protein-1 (MSP-1)-specific B5 TCR transgenic Tem survive better than Teff. Surprisingly, as Tem are associated with antigen persistence, Tem survive well even after clearance of infection. As previously shown during T cell contraction, TeffEarly, which can generate Tem, also survive better than other Teff subsets in uninfected recipients. Two other Tem survival mechanisms identified here are that low-level chronic infection promotes Tem both by driving their proliferation, and by programming production of Tem from Tcm. Protective CD4 T cell phenotypes have not been precisely determined in malaria, or other persistent infections. Therefore, we tested purified memory (Tmem) and Teff subsets in protection from peak pathology and parasitemia in immunocompromised recipient mice. Strikingly, among Tmem (IL-7Rαhi) subsets, only TemLate (CD62LloCD27-) reduced peak parasitemia (19%), though the dominant memory subset is TemEarly, which is not protective. In contrast, all Teff subsets reduced peak parasitemia by more than half, and mature Teff can generate Tem, though less. In summary, we have elucidated four mechanisms of Tem maintenance, and identified two long-lived T cell subsets (TemLate, TeffEarly) that may represent correlates of protection or a target for longer-lived vaccine-induced protection against malaria blood-stages.

Indexed as

AnimalsCD4-Positive T-LymphocytesImmunologic MemoryInterferon-gammaMalariaMiceMice, Inbred BALB CMice, Inbred C57BLPlasmodium chabaudiT-Lymphocyte SubsetsInterferon-gamma

Identifiers

PMID29630679
PMCPMC5908200

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.